AstraZeneca (AZN) had discussions with Bristol-Myers Squibb (BMY) through the spring and summer about a potential deal. By early August, talks about a mostly stock-based deal where AstraZeneca (AZN) would purchase Bristol-Myers (BMY) for a premium were